Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
2 Biotech Stocks You Can Buy and Hold for the Next Decade
09:00am, Sunday, 12'th Feb 2023
These companies could grow in prominence in the coming years.
Exelixis (EXEL) Q4 Earnings Top, Revenues Beat on Cabometyx
01:33pm, Wednesday, 08'th Feb 2023
Exelixis (EXEL) beats earnings and sales estimates for the fourth quarter due to increased Cabometyx sales volume.
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics
07:32am, Wednesday, 08'th Feb 2023
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street esti
Exelixis (EXEL) Q4 2022 Earnings Call Transcript
06:00am, Wednesday, 08'th Feb 2023 The Motley Fool
EXEL earnings call for the period ending December 31, 2022.
Exelixis (EXEL) Reports Q4 Loss, Tops Revenue Estimates
10:55pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Exelixis (EXEL) delivered earnings and revenue surprises of 40% and 1.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Exelixis, Inc. (EXEL) Q4 2022 Earnings Call Transcript
08:48pm, Tuesday, 07'th Feb 2023
Exelixis, Inc. (NASDAQ:EXEL ) Q4 2022 Results Conference Call February 7, 2023 5:00 PM ET Company Participants Susan Hubbard - EVP, Public Affairs and IR Mike Morrissey - President and CEO Chris Senne
Exelixis (EXEL) Reports Q4 Loss, Tops Revenue Estimates
07:34pm, Tuesday, 07'th Feb 2023
Exelixis (EXEL) delivered earnings and revenue surprises of 40% and 1.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL
03:30pm, Monday, 06'th Feb 2023 Zacks Investment Research
Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.
3 No-Brainer Stocks to Buy Right Now for Less Than $25
02:40pm, Saturday, 04'th Feb 2023 The Motley Fool
All three healthcare stocks are showing solid long-term potential.
3 No-Brainer Stocks to Buy Right Now for Less Than $25
09:40am, Saturday, 04'th Feb 2023
All three healthcare stocks are showing solid long-term potential.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
03:00pm, Tuesday, 31'st Jan 2023 Zacks Investment Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
11:45am, Tuesday, 31'st Jan 2023
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
03:00pm, Thursday, 26'th Jan 2023 Benzinga
Upgrades
According to Tigress Financial, the prior rating for Walmart Inc (NYSE:WMT) was changed from Neutral to Buy. In the third quarter, Walmart showed an EPS of $1.50, compared to $1.45 from the y
Exelixis' Patent Decision In Line With Expectations, But Analysts Say Stock Overhang Could Continue
06:17pm, Friday, 20'th Jan 2023 Benzinga
Exelixis Inc (NASDAQ: EXEL) announced that the U.S. District Court for the District of Delaware ruled in its favor, rejecting MSN Laboratories Private Limited's challenge to the cabozantinib compo
Exelixis: Building On A Blockbuster
07:24pm, Wednesday, 18'th Jan 2023
Exelixis' CABOMETYX is hitting on all cylinders. Exelixis has an interesting and highly cabozantinib-centric pipeline.
